Elicio Therapeutics, Inc.
ELTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001601485
No open-market purchases or sales by Elicio Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $15.3M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Elicio Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- 0 vs. Q2 2024
- Shares held
- 491.5K
- −88.3K (−15.2%) vs. Q2 2024
- Total value
- $2.48M
- +$83.8K (+3.5%) vs. Q2 2024
- New holders
- 4
- 6 more added
- Sold out
- 4
- 1 more reduced
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 48 | $15.3M |
| Q1 2026 | 47 | $28.2M |
| Q4 2025 | 37 | $16.6M |
| Q3 2025 | 28 | $20.9M |
| Q2 2025 | 21 | $11.2M |
| Q1 2025 | 24 | $9.80M |
| Q4 2024 | 17 | $2.25M |
| Q3 2024 | 18 | $2.48M |
| Q2 2024 | 20 | $2.68M |
| Q1 2024 | 18 | $3.08M |
| Q4 2023 | 18 | $2.78M |
| Q3 2023 | 18 | $2.80M |
| Q2 2023 | 15 | $2.71M |
| Q1 2023 | 28 | $2.56M |
| Q4 2022 | 30 | $3.98M |
| Q3 2022 | 38 | $4.71M |
| Q2 2022 | 43 | $5.90M |
| Q1 2022 | 47 | $13.8M |
| Q4 2021 | 53 | $20.3M |
| Q3 2021 | 47 | $69.3M |
| Q2 2021 | 41 | $66.5M |
| Q1 2021 | 41 | $92.0M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Elicio Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 245,262 | $1.23M | 0.00% | +18,965+8.4% | Added |
| Geode Capital Management, LLC | 71,574 | $360.1K | 0.00% | +66+0.1% | Added |
| CM Management, LLC | 50,000 | $251.5K | 0.20% | 00.0% | Unchanged |
| Northern Trust Corp | 30,769 | $154.8K | 0.00% | +19,589+175.2% | Added |
| State Street Corp | 21,900 | $110.2K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 19,693 | $99.1K | 0.00% | +19,693 | New |
| Meyer Handelman Co | 13,899 | $69.9K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 12,856 | $64.7K | 0.00% | +12,856 | New |
| Bridgeway Capital Management, LLC | 12,500 | $62.9K | 0.00% | 00.0% | Unchanged |
| CIBC Private Wealth Group, LLC | 7,000 | $42.6K | 0.00% | 00.0% | Unchanged |
| Steward Partners Investment Advisory, LLC | 1,554 | $7.82K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1,236 | $6.22K | 0.00% | +34+2.8% | Added |
| Tower Research Capital LLC (TRC) | 950 | $4.78K | 0.00% | +950 | New |
| UBS Group AG | 848 | $4.27K | 0.00% | +831+4,888.2% | Added |
| National Bank of Canada | 800 | $4.02K | 0.00% | −700−46.7% | Reduced |
| Citigroup Inc | 374 | $1.88K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 240 | $1.21K | 0.00% | +10+4.3% | Added |
| JPMorgan Chase & Co | 18 | $91 | 0.00% | +18 | New |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −48,720−100.0% | Sold out |
| Warberg Asset Management LLC | 0 | $0 | 0.00% | −11,801−100.0% | Sold out |
| Avion Wealth | 0 | $0 | 0.00% | −78−100.0% | Sold out |
| Arena Investors LP | – | – | – | – | Not filed |
| BlackRock Inc. | – | – | – | – | Not filed |